SS Innovations International enters the week after May Day with a sharp contrast between what the company just signalled and what bears have been doing.
A $150M shelf registration filed late on May 1 — the kind of filing that throws a ceiling over near-term price appreciation — landed on the same day the stock closed at $3.99, down 8.5% on the week and 20% over the past month. The filing is the dominant event shaping how traders read the setup right now.
The short-selling side of the ledger tells a strikingly different story, however. Short interest has collapsed. It shed 50% in a single week to just 73,000 shares, representing only 0.04% of the free float — a level so low it barely qualifies as a short position in any meaningful sense. The decline accelerated through late April: shares short were running near 214,000 as recently as early April and touched 249,000 in mid-March. That multi-month unwind appears complete. Cost to borrow, which peaked near 87% in late March and was still above 50% in early April, has eased to roughly 38% — expensive relative to the broad market but less than half its recent extreme. Availability has also loosened considerably: at 133% of short interest, there are more shares available to borrow than are currently borrowed, compared to the borrow squeeze conditions seen when availability was near zero in early April. The short-score reading of 57.7 is moderate and has been drifting lower through the week, consistent with a lending market that is unwinding rather than tightening.
What explains the short exit is not entirely clear, but the CEO and two other insiders provided a clue back in early March. CEO Sudhir Srivastava bought just under $2 million worth of shares on March 6 at $4.01. Executive Vice Chairman Frederic Moll added another $2 million at $3.99 the same day. Director Timothy Adams purchased $1.2 million at that level as well. Together, the three trades put $5.2 million of insider capital into the stock inside a single session, net of any sales. The stock is now trading right around those purchase prices — meaning those positions are essentially flat — and those were the most recent material insider trades on record.
Ownership is tightly concentrated. Srivastava personally holds 54.7% of shares outstanding and trimmed only modestly (3.2 million shares) in the most recent reported period. Frederic Moll, the da Vinci Surgical System co-inventor and industry heavy-hitter, holds another 10.2%. Manipal Global Health Services, a major Indian hospital group and a natural strategic partner, controls 7.5%. That top-three bloc controls roughly 72% of shares, which explains why short interest has never been a primary driver here and why the free float is small enough that even 73,000 shares shorted is a meaningful fraction of what actually trades.
The next earnings date is May 14. The prior three results events were unremarkable on price — a 2.2% one-day decline in March 2026 and a 3.6% bounce on an update in the same month, with a sharper 8.1% drop the previous November. None of those produced sustained directional moves. The May 14 print arrives with the shelf filing already in the public domain, so the dilution question is live regardless of what the numbers show. What traders will likely focus on is any update to the SSi Mantra surgical robot's commercial traction in the emerging markets that gained regulatory approvals earlier in the spring, and whether management elaborates on the purpose and timing of the shelf raise.
See the live data behind this article on ORTEX.
Open SSII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
